|
Lung Data Review – May 7, 2026
Our Lung Data Review was held virtually on May 7th, hosted by Dr. Edith A. Perez (Cornerstone's CMO) with our cochairs Dr. Tarek Mekhail, Dr. Eric Schaefer, and Dr. Sujith Kalmadi highlighting key practice changing data for EGFRm to HER2m NSCLC as well as SCLC disease presented over the last year providing a comprehensive review with discussion featuring interactive polling and live chat Q&A.
Dr. Edith Perez shared important information on Lambert-Eaton Myasthenic Syndrome (LEMS) often associated with SCLC noting the impact that this rare autoimmune neuromuscular junction disorder can have on patients and the approved treatment option that can provide benefit.
We thank the more than 100 attendees who joined us for the evening! Click here to access slides & video
| Click the image to download | |
We’re excited to announce a strategic partnership between Cornerstone Specialty Network and Knowtex to advance AI-driven clinical workflows across community oncology and multispecialty practices. By leveraging voice-enabled AI technology, this collaboration will streamline documentation, automate medical coding, and integrate directly into EMR platforms—helping reduce administrative burden, improve operational efficiency, and enhance patient care. This is another step forward in our commitment to strengthening independent community oncology practices nationwide. Click here to read the full press release
If interested in learning more, please contact Tony Gucciardo agucciardo@cornerstoneonc.com
| | | | | May is National Cancer Research Month (NCRM), we want to recognize and sincerely thank our network whose dedication makes meaningful research possible. We are grateful for your partnership, your expertise, and your continued commitment to driving progress in cancer care in the community setting through Cornerstone Clinical Investigations. | | | As of May 8, 2026 enrollment in our clinical investigation study, Retrospective Observational Study on HR+ and HER2-Low (IHC 1+ or 2+ with ISH negative) and HER2-Ultralow (IHC 0 with membrane staining) Metastatic Breast Cancer [Protocol CSNDSI01] sponsored by DSI is complete. Thank you to all our study participants! | |
Our latest clinical investigation study Retrospective Chart Review to Characterize Real-World Use, Clinical Outcomes, and Safety of Datopotamab Deruxtecan (Dato-DXd) in EGFR-Mutated NSCLC Following FDA Approval (June 23, 2025), Including Treatment Patterns and Outcomes Among Participants Eligible for Dato-Dxd [Protocol CSNDSI02] sponsored by DSI has enrolled its first patients! Congratulations Highlands Oncology! We are looking forward to engaging with sites and welcome additional participation!
- Highlands Oncology Group - 6 patients
If interested in participating in any of our clinical trials, please contact Rachel M. Condjella, Ph.D. — Senior Director of Clinical Investigations & Market Insights rcondjella@cornerstoneonc.com
| | | Our next COLAI meeting will take place virtually on June 10th discussing "Strategic Evaluation and Implementation of AI into Community Practices". This session will explore how community oncology leaders can navigate the increasingly complex AI landscape and implement AI solutions that can improve efficiency, drive revenue, and support high-quality patient care. | | | | | Our upcoming virtual ASCO Symposium will occur on July 16th with our cochairs Dr. Edith A. Perez, Dr. Eric Schaefer, and Dr. Sujith Kalmadi highlighting key data presented at the 2026 ASCO Annual Meeting in Chicago from May 29th - June 2nd. Click below to join the waitlist. | | | | | Our virtual Nurse Symposium will occur on August 20th. An interactive program intentionally created for Community Oncology Integrated Nursing and Advanced Practice Providers. Click below to join the waitlist. | | | | | |
Cornerstone Specialty Network's National Fall Summit will be held on October 9-10, 2026 at the JW Marriott Miami, Turnberry, FL.
Space is Limited.
Click below to join the waitlist.
| | | Your News, Our Newsletter! | | | We want to hear from you! Share your exciting projects, upcoming events, or personal milestones with the Cornerstone Specialty Network community. | |
Follow us on LinkedIn to stay up to date with the latest happenings at Cornerstone!
LinkedIn is much more than a platform for jobseekers and career development or building business relationships. Community oncologists can benefit enormously from being active on LinkedIn: it’s a low‑lift way to stay visible in a rapidly evolving field, connect with peers facing similar operational and clinical challenges, and access real‑time updates on trials, guidelines, and policy changes that directly affect community practice.
| | | |
FDA Updates for May 2026
On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy evaluated in the VERITAC-2 trial. Read More
| | | | |
Thank You
Cornerstone would like to take this opportunity to thank our select pharma partners for their support of our programs enabling us to provide unique opportunities to connect with our network, deliver key educational programs, and ultimately benefit patient care.
| | | | | |
